BioSpace News Archive

- Revenues for full year 2020 now expected to be $8.4-8.8 billion compared to the previous outlook of $8.0-8.6 billion - Reported diluted earnings per share (EPS) for full year 2020 now expected to be $7.42-$8.92 compared to the previous outlook of $5.66-$7.66 - Adjusted diluted EPS for full year 2020 now expected to be $7.50-$9.00 compared to the previous outlook of $6.60-$8.60 - Cash provided by operations for full year 2020 now expected to be at least $1.45 billi

AIM ImmunoTech Inc. (NYSE American:AIM) today announced that the company will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020.

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced three presentations for its TransCon PTH program for hypoparathyroidism (HP) at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event, taking place September 11–15. In addition, results from the randomized, double-blind phase 2 PaTH Forw

Moderna expands footprint in North America with Canadian subsidiary; permanent presence to support delivery of mRNA vaccines and therapeutics to Canadians CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the appointment of Michael Mullette as Managing Director, Canad

First study to compare percutaneous arteriovenous fistula devices reports positive clinical outcomes

Genetic sequencing research laboratory Progenabiome published findings on SARS-CoV-2 in fecal samples from symptomatic patients who tested positive for COVID-19.

Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that an abstract featuring data from an exploratory analysis of the ARIEL3 clinical study evaluating Rubraca

Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President & Chief Executive Officer, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020, at 2:00 PM ET. The Company will present virtually and provide updates about re

Today, Johnson & Johnson Medical Devices Companies introduces My Health Can’t Wait, an educational effort and resource hub, aimed to inspire people to prioritize their health and get the information they need to pursue care with confidence

Ultravision™ Controls Aerosolized Particles in Laparoscopic Surgery, Leading to Cleaner Air in the Operating Room